Vanguard Group
PRME icon

Vanguard Group’s Prime Medicine PRME Stock Holding History

Vanguard Group’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$22.4M Buy
6,467,872
+1,546,007
+31% +$6.88M ﹤0.01% 2567
2025
Q3 		$27.3M Buy
4,921,865
+1,294,355
+36% +$5.26M ﹤0.01% 2468
2025
Q2 		$8.96M Sell
3,627,510
-13,838
-0.4% -$21.3K ﹤0.01% 2962
2025
Q1 		$7.25M Sell
3,641,348
-13,969
-0.4% -$35.6K ﹤0.01% 3022
2024
Q4 		$10.7M Sell
3,655,317
-1,234,996
-25% -$4.34M ﹤0.01% 2918
2024
Q3 		$18.9M Sell
4,890,313
-1,188,540
-20% -$5.51M ﹤0.01% 2613
2024
Q2 		$31.2M Buy
6,078,853
+277,408
+5% +$1.68M ﹤0.01% 2348
2024
Q1 		$40.6M Buy
5,801,445
+1,746,534
+43% +$13.2M ﹤0.01% 2258
2023
Q4 		$35.9M Buy
4,054,911
+103,118
+3% +$794K ﹤0.01% 2324
2023
Q3 		$37.7M Buy
3,951,793
+617,310
+19% +$8.02M ﹤0.01% 2262
2023
Q2 		$48.9M Buy
3,334,483
+2,450,037
+277% +$34.2M ﹤0.01% 2192
2023
Q1 		$10.9M Buy
884,446
+11,923
+1% +$194K ﹤0.01% 2887
2022
Q4 		$16.2M Buy
+872,523
New +$15.8M ﹤0.01% 2723

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group's PRME Position: Q4 2025 in Review

Vanguard Group increased its Prime Medicine (PRME) stake by 31% in Q4 2025, buying an estimated $6.88M and bringing the position to 6,467,872 shares worth $22.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Vanguard Group first reported a position in PRME in Q4 2022 and has held it in 13 quarters since. The position peaked at $48.9M in Q2 2023. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Vanguard Group held 6,467,872 shares of Prime Medicine worth $22.4M as of Q4 2025.
  • Vanguard Group bought 1,546,007 Prime Medicine shares in Q4 2025, an estimated $6.88M.
  • Prime Medicine made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2567 holding.
  • Vanguard Group first reported a position in Prime Medicine in Q4 2022 and has held it in 13 quarters since.
  • Vanguard Group's Prime Medicine position peaked at $48.9M in Q2 2023.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.